Status:

NOT_YET_RECRUITING

Plant-Based Nutrition for Breast or Endometrial Cancer

Lead Sponsor:

University of Rochester

Conditions:

Breast Cancer Metastatic

Endometrial Cancer Stage IV

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

This is a randomized controlled trial of a whole food, plant-based (WFPB) dietary intervention among women with metastatic breast or endometrial cancer.

Detailed Description

This is a randomized controlled trial of a whole food, plant-based (WFPB) dietary intervention among women with metastatic breast or endometrial cancer. It is designed to explore whether this dietary ...

Eligibility Criteria

Inclusion

  • • Female sex (as assigned at birth), aged 18 years or older
  • A confirmed diagnosis of endometrial or metastatic breast cancer. All subtypes are eligible
  • Treating oncologist approval and expected survival of at least six months
  • Undergoing any systemic treatment including hormonal, cytotoxic, targeted monoclonal antibody or small molecule kinase inhibitors or any combination of the above. Women who have active cancer and have been recommended but declined systemic treatment are also eligible.
  • Willing to adopt a strict, whole-foods, plant-based diet
  • Willing and able to comply with the WFPB protocol for the duration of the study including scheduled testing, Zoom meetings, and office visits
  • Able to speak and read English fluently.
  • Women with plans for radiation therapy or surgery are also eligible provided that they meet all other eligibility criteria.

Exclusion

  • • BMI ≤ 20.0 kg/m2
  • Inability to tolerate a normal diet
  • Active malabsorption syndrome at time of consent, as determined by study physicians (i.e. Crohn's disease, bowel surgery)
  • Any food allergies or intolerances that would interfere with study compliance
  • Recent consumption (in the past six months) of a vegan diet
  • eGFR \< 30 on ≥ two lab tests in the past six months
  • Serum potassium \> 5.4 in the past six months
  • Current insulin or sulfonylurea use
  • Current warfarin use (non-vitamin K antagonist allowed)
  • High-risk alcohol use (\>7 drinks/wk)
  • Illicit substance use (not including marijuana)
  • Cognitive impairment or psychiatric disorder impairing ability to give consent.

Key Trial Info

Start Date :

December 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2029

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT07189702

Start Date

December 1 2025

End Date

December 1 2029

Last Update

September 24 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.